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Abstract
Cholangiocarcinoma (CC) is a rare cancer arising from the epithelium of the biliary tree, anywhere
from the small peripheral hepatic ducts to the distal common bile duct. Classification systems for
CC typically group tumours by anatomical location into intrahepatic, hilar or extrahepatic
subtypes. Surgical resection or liver transplantation remains the only curative therapy for CC but
up to 80% of patients present with advanced, irresectable disease. Unresectable CC remains
resistant to many chemotherapeutic agents, although gemcitabine, particularly in combination with
other agents, has been shown to improve overall survival. Ongoing investigation of biological
agents has also yielded some promising results. Several novel interventional and endoscopic
techniques for the diagnosis and management of non-operable CC have been developed: initial
results show improvements in symptoms and progression-free survival but further randomised
studies are required to establish their role in the management of CC.
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Introduction
Cholangiocarcinoma (CC) is a rare tumour of cholangiocytes (epithelia of the biliary tract)
[1] with an incidence in the UK of approximately 1–2 per 100,000 population [2, 3].
However, the incidence (particularly of intra-hepatic tumours) continues to rise annually
both within the UK and worldwide [3–6], and in the mid-1990s CC overtook hepatocellular
carcinoma as the commonest cause of liver cancer death in the UK [7]. Established risk
factors for CC include male sex, increasing age, smoking and diabetes [4].
Up to 70% of CC arise from the hilar region (also known as Klatskin tumours) and involve
the main extrahepatic bile duct and right or left hepatic ducts [1]. Almost all other tumours
are extrahepatic, involving the distal common bile duct [1]. Hilar and extrahepatic tumours
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typically cause progressive occlusion of the external biliary tree and present with painless
obstructive jaundice, with or without cholangitis. Only rarely do tumours arise from smaller
intrahepatic bile ducts, often forming a solitary, compressive mass that may result in non-
specific symptoms such as right upper quadrant discomfort, anorexia and nausea.
The late presentation of CC patients is thought to be due in part to a lack of consistently
effective biomarkers and diagnostic tools for the detection of early disease. CA
(carbohydrate antigen) 19-9 remains the most widely used biomarker for the diagnosis of
CC; however, it is undetectable in approximately 7% of the population who are deficient in
the fucosyltransferase enzyme required for its production [8, 9]. CA19-9 is also non-specific
and can be elevated in pancreatic adenocarcinoma, primary biliary cirrhosis, cholestasis,
cholangitis and in smokers [10]. However, a combination of CA19-9, magnetic resonance
cholangiopancreaotography (MRCP) and endoscopic or percutaneous tissue sampling
represents the standard technique for diagnosing CC. Recently, several novel endoscopic
techniques such as per-oral cholangioscopy, confocal endomicroscopy and fluorescence in
situ hybridisation (FISH) of biliary brushings have been shown to enhance the accuracy of
standard ERCP in diagnosing CC [11– 13].
Prognosis in unresectable CC is poor (6–12 months) and therapeutic options have
historically been limited. However recent combinations of chemotherapy agents, biological
therapies and novel local therapies have been shown to be associated with significant
improvements in overall survival. Due to the rarity of the disease many of these treatments
have so far only been evaluated in small studies and validation through larger prospective
studies will be required to ultimately define their role in future algorithms for the
management of CC.
Surgical Management of Resectable CC
i. Pre-operative assessment and optimisation
Only a minority of patients with CC (15–35%) are suitable for surgical treatment.
Assessment of suitability relies on accurate cross-sectional imaging and endoscopic
modalities to characterise the tumour’s anatomical site as well as the extent of local and
metastatic spread [4, 14–17]. However, gradual infiltration along the biliary tract, associated
with the common presence of low volume but multifocal disease can result in CC being
under-staged by cross-sectional imaging. Although ultrasound and high-resolution computed
tomography (CT) are useful for the initial assessment of the liver and biliary system and to
exclude metastatic spread, magnetic resonance imaging (MRI) with contrast angiography
provides the most accurate assessment of biliary anatomy, local invasion and the extent of
involvement of crucial nearby ductal and vascular structures, with a reported accuracy in
localising the site and cause of biliary obstruction of 100% and 95%, respectively [18].
The current use of positron-emission computed tomography (PET-CT) in patients with
suspected CC remains limited due to lack of access and the common presence of cholangitis,
which can make interpretation difficult; however, its use may become more important in the
future [19, 20]. Cytological or histological confirmation is usually obtained following cross-
sectional imaging, commonly by endoscopic retrograde cholangiopancreatography (ERCP).
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Endoscopic techniques remain crucial as the majority of patients diagnosed have
unresectable disease and provision of adequate biliary drainage is necessary to prevent
sepsis and enable palliative chemotherapy. However, when employed for diagnostic
purposes, standard ERCP and brush cytology has a sensitivity for malignancy of only 9–
57% [21–24], although this may be improved by techniques such as FISH and digital image
analysis, which enable the analysis of DNA abnormalities in brush cytology [23]. Further
techniques, such as methylene blue, narrow-band imaging, autofluorescence, confocal laser
endomicroscopy and elastic scattering spectroscopy are not routinely used but may allow an
augmented view of the visualised mucosa during ERCP [25–28].
Alternative endoscopic methods include endoscopic ultrasonography with fineneedle
aspiration (EUS-FNA), which provides a method for visualising and sampling the
extrahepatic biliary tree, hilar masses, and peri-hilar ductal and vascular structures, with a
sensitivity and specificity of up to 89% and 100% respectively [29]; or single operator
cholangioscopy systems (Spyglass, Boston Scientific Corp, Natick, Massachusetts, USA). In
cases of uncertainty regarding resectability, staging laparoscopy can provide additional
information about tumour extension, liver atrophy or metastatic disease and approximately a
third of such patients will be found to have irresectable disease [17, 30, 31].
Pre-operative biliary drainage in the presence of jaundice, via endoscopically-placed bile
duct stents, leads to improvements in liver function and outcome following hepatic resection
[32–35]. Percutaneous, transhepatic radiological techniques (e.g. PTC, percutaneous
transhepatic cholangiography) for drainage of unilateral bile ducts can also be used and may
have a similar or lower complication and failure rate than endoscopic techniques [33–39].
Portal vein embolization or ligation should also be utilised pre-operatively to promote
hypertrophy of the liver remnant in situations where it is predicted to be less than 25% or
there is unresolved pre-operative jaundice, and is associated with a reported reduction in
post-operative hepatic failure from 20% to 6% [40–43]. Such improvements in pre-operative
optimisation have led to a growing number of patients with CC being eligible for surgical
resection [16].
ii. Surgical resection
Tumour resection with clear pathological margins offers the best long-term survival and
recurrence rates in CC: an aggressive resectional strategy is therefore the mainstay of
treatment [4,15,16]. Hepatic resection with concurrent excision and anastomosis of the
portal vein and/or bile duct is considered standard treatment and has been associated with a
reduction in associated morbidity and mortality [44, 45]. Specific complication, survival and
recurrence rates following surgery are related to the precise nature of the surgery the patient
undergoes, which in turn, is dictated by the anatomical site and extent of the tumour.
Patients with intra-hepatic tumours will require segmental liver resection or hemi-
hepatectomy; those with extra-hepatic bile duct tumours will undergo hilar and bile-duct
resection, with partial hepatic resection if the bile-duct bifurcation is also affected; and
ampullary or distal bile duct tumours will be resected by Whipples
pancreaticodudoenectomy [7, 46].
Skipworth et al. Page 3
Dig Dis. Author manuscript.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
30-day mortality following a resection for CC ranges from 2% to 25% in various series with
significant complications including bile leak, cholangitis, haemorrhage and intra-abdominal
collections, occurring in up to approximately two thirds of patients [15, 17, 43, 47–51].
Mortality rates are increased in those with significant co-morbidities, hypoalbuminaemia
and jaundice in the pre-operative period [15, 17, 43, 47–51] but is now similar in those
undergoing extended resection (with or without vascular resection) and those less extensive
hepatic resection [49, 50, 52]. The commonest post-operative complication contributing to
patient death remains hepatic failure, the risk of which increases with the amount of hepatic
tissue resected [48, 50]. ALPPS (Associating Liver Partition with Portal vein ligation for
Staged hepatectomy) is a novel two-stage resection technique involving initial in-situ
transection of liver parenchyma (along the intended line of hepatic resection or falciform
ligament) and portal vein ligation, with subsequent staged (7–14 days later) completion
hepatectomy [53]. When compared to portal vein embolization, this strategy results in rapid
volume growth of the future liver remnant (FLR; up to 75% increase) with the most rapid
growth occurring within the first three days of the procedure. This technique thereby enables
resection of tumours that would have been previously considered to be unresectable because
of the predicted small size of the FLR. ALPPS can also be utilised following initial portal
vein embolization if there has been insufficient FLR volume increase [53, 54].
CC is associated with a median overall five-year survival of 20–36 months; however, in
those patients in whom complete pathological resection is possible [16, 17, 55–57], median
survival increases to 65 months [4, 16, 48, 52]. Median survival rates also vary according to
the site of the tumour (hilar tumours 18–30 months, perihilar tumours 12–24 months,
extrahepatic 16–30 months) [6, 15, 58–61] and the presence of post-operative residual
disease, which leads to a significant decrease in survival rates [62].
Factors that have been associated with prolonged post-operative survival include small,
early stage or well-differentiated, unifocal tumours, without regional nodal disease or
macroscopic portal vein invasion [4, 15–17, 49]. However, even following successful
resection, recurrence is common, occurring in up to 63% overall within two years [4].
iii. Liver transplantation
Liver transplantation negates any requirements for negative resection margins following en-
bloc resection of the liver, bile ducts and hilar lymphatics, but remains limited by the
scarcity of donors.
Recent results have suggested that a combination of orthotopic transplantation and neo-
adjuvant chemoradiotherapy regimens offer excellent long-term (five-year) survival rates of
up to 82% in patients previously considered unresectable [63–65]. Recurrence rates are also
lower than in resected patients (13% vs. 27%) [63]. However, there are difficulties in direct
comparison with resected patients in that transplanted patients tend to be younger, have
fewer co-morbidities, have nodenegative disease and almost always undergoing neo-
adjuvant therapy [66].
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Treatment of Locally Advanced and Metastatic CC
The prognosis for patients with locally advanced or recurrent CC is poor. The goals of
palliative therapy in such patients are to relieve symptoms and improve overall quality of
life. There is no role for tumour debulking in advanced CC.
i. Endoscopic biliary decompression in malignant obstruction
Biliary drainage is essential in CC to prevent septic complications from cholangitis and
enable patients to be eligible for palliative chemotherapy. Effective endoscopic biliary
stenting to relieve obstruction has been associated with fewer short term complications and
longer survival (19 vs. 16.5 months), as well as being more cost-effective than surgical
decompression [67]. In most centres endoscopic or percutaneous management of biliary
obstruction is therefore the standard initial approach in treating patients with malignant
biliary obstruction.
i. a. Distal CBD obstruction—A meta-analysis of seven studies (1992–2006) compared
plastic stents to selfexpanding metal stents (SEMS) for malignant distal biliary obstruction
and found that the relative risk of recurrent biliary obstruction was significantly lower
(RR=0.52) in the metal stent group [68]. Since uncovered SEMS are permanent, many
patients are initially managed with a plastic stent while confirmation of malignancy is
obtained. However, the introduction of removable covered metal stents has changed this
practice. Four randomised controlled trials have compared uncovered and covered SEMS in
the management of distal biliary obstruction: in the earlier three studies, no significant
differences in stent patency time, survival or complication rates were observed but covered
stents did migrate more frequently [69–71]. However, in the most recent randomised trial
incorporating patients with distal biliary obstruction secondary to pancreatic carcinoma,
survival without stent dysfunction was significantly longer in the covered SEMS group (187
vs. 132 days, P=0.043) and no difference in stent migration was observed [72].
i.b. Proximal biliary obstruction—Hilar CC can lead to disconnection of the right and
left biliary systems and several studies have attempted to define optimal stenting practice in
this situation. A prospective, observational study reported that plastic stent placement was
associated with a poorer 30 day outcome (cholangitis, stent occlusion, migration,
perforation, unplanned ERCP or PTC) compared with metal stents (OR 6.32; 95%
confidence interval 1.23, 32.56) [73].
A single biliary stent will achieve decompression in most patients (80%) with hilar CC [74,
75]; however, in a retrospective study comparing the efficacy of unilateral and bilateral stent
placement, functional success was significantly higher (97.9% vs. 84.8%, p<0.001) and
complications fewer (56.4% vs. 24.4%, p<0.001) in the bilateral SEMS group. Placement of
SEMS rather than plastic stents was also associated with longer stent patency times (24 vs.
29 weeks, p<0.0001) [76]. A further randomised study observed that rates of successful
drainage were significantly higher following SEMS placement (70.4% vs.46.3%, p=0.1) and
overall survival was longer (126 vs. 49 days, p=0.002) [77].
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ii. Novel endoscopic and percutaneous local and ablative therapies
ii.a. Photodynamic Therapy—Photodynamic therapy (PDT) is a novel ablative
technique that results in localised tissue necrosis following the application of either visible
or near-infrared light (usually from a low-power, red laser) after prior administration of a
photosensitising agent. Randomised studies comparing PDT with biliary stenting with
stenting alone have provided conflicting results. Initial studies reported prolonged stent
patency and improved survival after PDT [78, 79]; however, a subsequent UK phase III
study closed early as overall survival was longer in those treated with stenting alone [80].
ii.b. Radiofrequency ablation—Radiofrequency ablation (RFA) in combination with
SEMS placement has been evaluated in a small study of 22 patients, which found that all
stents were patent 30 days after the procedure [81]. Only rarely centres have centres
described the use of RFA alone to achieve biliary drainage and randomised controlled trials
are on-going to evaluate this technique [82]. Current guidance from the National Institute for
Health and Care Excellence in the UK recommends that the treatment is only carried out in
specialist centres in the context of clinical trials [83].
iii. Transarterial chemoembolization (TACE)
Transarterial delivery of embolic and cytotoxic agents leads to local tumour ischaemia and
targeted chemotherapy, which, in unresectable hepatocellular carcinoma, has been
associated with improved survival and resulted in its incorporation into many standard
treatment algorithms [84]. Recently, it has been used in the treatment of advanced CC: a
prospective study of 115 patients with unresectable CC treated with TACE found that more
than half of the patients survived over one year (median survival 13 months) [85]. A recent
retrospective study has also observed TACE to be an equivalent treatment to surgery for CC
in those in whom an R0 resection (negative pathological margins) was not achieved [86].
iv. Chemotherapy
A multicentre, randomised phase III study comparing cisplatin and gemcitabine to
gemcitabine alone in the treatment of advanced biliary tract cancer (ABC-02) was associated
with an improved median survival in the combination group (11.7 vs. 8.1) [87]. Improved
progression free survival and disease control rates were also demonstrated. Prior to the
ABC-02 trial patients with advanced CC received a range of chemotherapy regimens;
however, a large retrospective review from the UK compared overall survival in patients
receiving gemcitabine, fluoropyrimidine or platinum-based treatments and found that
fluropyrimidine may be as effective as gemcitabine in the treatment of advanced CC [88].
Initial prospective studies which combined gemcitabine- and fluropyrimidine-based
treatments observed prolonged survival (14 months) with relatively few complications [89].
iv.a. Neo-Adjuvant chemoradiotherapy for CC—The primary aim of neo-adjuvant
therapy is to downstage malignant disease, rendering tumours suitable for surgical resection
or transplantation. In other solid organ malignancies both radio- and chemotherapy have
been observed to be more effective in the neo-adjuvant setting. In unresectable perihilar CC,
a large case series included 287 patients from 12 large-volume transplant centres in the US.
71 patients did drop out prior to liver transplantation but recurrence-free survival rates were
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78% and 65% at 2 and 5 years respectively[90]. A further case series of 45 patients with
extrahepatic disease, 12 of whom were treated neo-adjuvantly. Three had a complete
pathological response and 11 were able to undergo R0 resection. In addition, despite having
more advanced disease at presentation, those who received neo-adjuvant chemoradiotherapy
had a longer five-year survival (53% vs. 23%, p=0.16)[91]. Although these results are
promising, currently neo-adjuvant regimens are not part of the standard management of CC.
iv.b. Adjuvant chemotherapy for CC—Postoperative adjuvant therapy is widely
recommended for all patients with intrahepatic or extrahepatic CC who have
microscopically positive resection margins, as well as for those with a complete resection
but node-positive disease. However even following R0 resection in CC, loco-regional
recurrence remains high. Currently there is no established treatment protocol for those
patients undergoing attempted curative resection for CC but in whom negative histological
margins are not achieved. Small studies of adjuvant therapy have demonstrated promising
results; the outcome of the UK BILCAP randomised controlled trial, which is evaluating the
role of adjuvant chemotherapy with capecitabine (an oral 5-fluorouracil analogue),
following surgical resection, is awaited.
v. Radiotherapy
External beam radiotherapy and intraluminal brachytherapy have been evaluated in CC [92–
94]. Most studies to date have compared patients with historical controls and results have
been equivocal. McMasters et al [95] described a case series of nine patients with
extrahepatic CC who were successfully down-staged with external beam radiotherapy:
100% had negative resection margins following surgery. However, in a longer term study by
Gonzalez et al [96], which used combinations of pre- and post-operative external beam
radiotherapy, no impact on one, three or five year survival was observed. More recently
Gwak et al [97] observed a downward trend in five-year survival following adjuvant
radiotherapy (21% vs. 11.6%). Thus, large prospective studies are lacking and at present the
evidence does not support the use of adjuvant radiotherapy in patients with negative
resection margins [98].
Few studies have evaluated chemoradiotherapy in CC. Kim et al [99] followed 72
extrahepatic CC patients that had undergone surgical resection (47 with negative margins
and 25 with positive margins) and then went on to receive post-operative external beam
radiotherapy (40Gy) and concomitant boluses of 5-FU (500mg/m2): the five-year survival
rates were 36% following R0 resection, 35% following R1 resection and 0% following R2
resection. Nakeeb et al [100] similarly reported improved survival with chemoradiotherapy.
Although these studies are small, they appear to support the use of radical resection followed
by chemoradiotherapy in CC.
vi. Biological therapies
To date, several pilot studies have investigated the role of molecularly targeted therapies in
CC. For example, in vitro studies of the multi-kinase inhibitor sorafenib has shown that it
inhibits proliferation of CC cell lines in culture in a dose-dependent manner [101] and
causes significant tumour suppression in a rodent model [102]. However, limited phase II
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studies to date in CC have not demonstrated a clinical benefit [103]. The French BINGO
trial randomised 101 patients to receive gemcitabine and oxaliplatin (GEMOX) with or
without cetuximab [104]. Initial findings demonstrated four-month progression free survival
rates of 50% in the GEMOX arm and 61% in the GEMOX with cetuximab arm.
Conclusion
Despite significant advances in the treatment of patients with CC, the only potential for
long-term survival remains surgical resection or liver transplantation. Unfortunately, this
remains only possible in a minority of patients and both neo-adjuvant and adjuvant therapies
currently provide only a limited survival improvement in selected patients with advanced
disease. To achieve improved outcomes, better understanding of tumour biology, combined
with the development of novel diagnostic and treatment strategies, is crucial.
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Glossary
USS Ultrasound
MRCP Magnetic Resonance Cholangiopancreatography
MRA Magnetic Resonance Angiogram
CA Carbohydrate Antigen
CEA Carcinoembryonic Antigen
CT Computed Tomography
ERCP Endoscopic Retrograde Cholangiopancreatography
PVE Portal Vein Embolization
ALPPS Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy
OLT Orthotopic Liver Transplantation
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Figure 1.
Current algorithm for the management of indeterminate biliary strictures or suspected
cholangiocarcinoma (Adapted from Skipworth et al [105]).
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